Literature DB >> 10773093

Antisense delivery using protamine-oligonucleotide particles.

M Junghans1, J Kreuter, A Zimmer.   

Abstract

Protamine, a polycationic peptide (mol. wt 4000-4500), was evaluated as a potential penetration enhancer for phosphodiester antisense oligonucleotides (ODNs). Unique complexes in the form of nanoparticles were spontaneously formed, which we call 'proticles'. The stability of the particles and the ODNs bound into the proticles was examined in foetal calf serum and cell culture medium. FITC-labelled ODNs bound to protamine showed an increased cellular uptake into human histiocytic lymphoma U 937 cells compared to free ODNs. Proticles significantly decreased cellular growth in a cell proliferation assay using ODNs against the c- myc proto-oncogene.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10773093      PMCID： PMC105384          DOI： 10.1093/nar/28.10.e45

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN： 0305-1048            Impact factor:   16.971


  27 in total

1.  Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.

Authors:  S Gryaznov; T Skorski; C Cucco; M Nieborowska-Skorska; C Y Chiu; D Lloyd; J K Chen; M Koziolkiewicz; B Calabretta
Journal:  Nucleic Acids Res       Date:  1996-04-15       Impact factor: 16.971

2.  Looking death in the eye: apoptosis and cancer research. Is cancer really caused by cells refusing to commit suicide on cue?

Authors:  S M Edgington
Journal:  Biotechnology (N Y)       Date:  1993-07

3.  Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells.

Authors:  Y Shi; H G Hutchinson; D J Hall; A Zalewski
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

Review 4.  Current concepts in antisense drug design.

Authors:  J F Milligan; M D Matteucci; J C Martin
Journal:  J Med Chem       Date:  1993-07-09       Impact factor: 7.446

5.  c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.

Authors:  L A Robinson; L J Smith; M P Fontaine; H D Kay; C P Mountjoy; S J Pirruccello
Journal:  Ann Thorac Surg       Date:  1995-12       Impact factor: 4.330

6.  Targeted delivery of antisense oligonucleotides by molecular conjugates.

Authors:  B A Bunnell; F K Askari; J M Wilson
Journal:  Somat Cell Mol Genet       Date:  1992-11

7.  Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy.

Authors:  R Bergan; Y Connell; B Fahmy; L Neckers
Journal:  Nucleic Acids Res       Date:  1993-07-25       Impact factor: 16.971

8.  Potentiation of cationic liposome-mediated gene delivery by polycations.

Authors:  X Gao; L Huang
Journal:  Biochemistry       Date:  1996-01-23       Impact factor: 3.162

9.  Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum.

Authors:  S Capaccioli; G Di Pasquale; E Mini; T Mazzei; A Quattrone
Journal:  Biochem Biophys Res Commun       Date:  1993-12-15       Impact factor: 3.575

10.  Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.

Authors:  O Zelphati; J L Imbach; N Signoret; G Zon; B Rayner; L Leserman
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971
View more
  21 in total

Review 1.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

2.  A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery.

Authors:  Xiaojuan Yang; Yong Peng; Bo Yu; Jianhua Yu; Chenguang Zhou; Yicheng Mao; L James Lee; Robert J Lee
Journal:  Mol Pharm       Date:  2011-03-23       Impact factor: 4.939

3.  In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice.

Authors:  Yoon Shin Park; Allan E David; Yongzhuo Huang; Jun-Beom Park; Huining He; Youngro Byun; Victor C Yang
Journal:  J Control Release       Date:  2012-04-23       Impact factor: 9.776

Review 4.  Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.

Authors:  Eun Ji Chung; Matthew Tirrell
Journal:  Adv Healthc Mater       Date:  2015-06-17       Impact factor: 9.933

5.  Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.

Authors:  Xiaojuan Yang; Chee Guan Koh; Shujun Liu; Xiaogang Pan; Ramasamy Santhanam; Bo Yu; Yong Peng; Jiuxia Pang; Sharon Golan; Yeshayahu Talmon; Yan Jin; Natarajan Muthusamy; John C Byrd; Kenneth K Chan; L James Lee; Guido Marcucci; Robert J Lee
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

6.  Novel siRNA delivery system to target podocytes in vivo.

Authors:  Peter V Hauser; Jeffrey W Pippin; Cora Kaiser; Ronald D Krofft; Paul T Brinkkoetter; Kelly L Hudkins; Dontscho Kerjaschki; Jochen Reiser; Charles E Alpers; Stuart J Shankland
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

7.  Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.

Authors:  Chee Guan Koh; Xulang Zhang; Shujun Liu; Sharon Golan; Bo Yu; Xiaojuan Yang; Jingjiao Guan; Yan Jin; Yeshayahu Talmon; Natarajan Muthusamy; Kenneth K Chan; John C Byrd; Robert J Lee; Guido Marcucci; L James Lee
Journal:  J Control Release       Date:  2009-08-28       Impact factor: 9.776

8.  Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide.

Authors:  Yoon Shin Park; Yongzhuo Huang; Yoon Jeong Park; Allan E David; Lindsay White; Huining He; Hee Sun Chung; Victor C Yang
Journal:  J Control Release       Date:  2010-01-28       Impact factor: 9.776

9.  Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier.

Authors:  Ingrid Kratzer; Karin Wernig; Ute Panzenboeck; Eva Bernhart; Helga Reicher; Robert Wronski; Manfred Windisch; Astrid Hammer; Ernst Malle; Andreas Zimmer; Wolfgang Sattler
Journal:  J Control Release       Date:  2006-11-28       Impact factor: 9.776

Review 10.  Use of Protamine in Nanopharmaceuticals-A Review.

Authors:  Ivana Ruseska; Katja Fresacher; Christina Petschacher; Andreas Zimmer
Journal:  Nanomaterials (Basel)       Date:  2021-06-07       Impact factor: 5.076
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.